XFEL beta2 AR structure by ligand exchange from Alprenolol to Alprenolol.

(2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate

Toward G protein-coupled receptor structure-based drug design using X-ray lasers.

Fusion protein of Beta-2 adrenergic receptor and T4 Lysozyme

Beta-2 adrenoreceptor,Beta-2 adrenoceptor,Lysis protein,Lysozyme,Muramidase

MKTIIALSYIFCLVFADYKDDDDAMGQPGNGSAFLLAPNRSHAPDHDVTQQRDEVWVVGMGIVMSLIVLAIVFGNVLVIT
AIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIWTLCVIAVDRYFAIT
SPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYAEETCCDFFTNQAYAIASSIVSFYVPLVIMV
FVYSRVFQEAKRQLNIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNTNGVITKDEAEKLF
NQDVDAAVRGILRNAKLKPVYDSLDAVRRAALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLAKSRWYNQTPNRAK
RVITTFRTGTWDAYKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCR
SPDFRIAFQELLCLRRSSLKHHHHHH

0.1 M HEPES pH 7.0, 0.1 M Ammonium Sulfate, 30% (v/v) PEG 400, 2 mM Alprenolol

National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

AUTHORS STATE THAT THE BIOLOGICAL UNIT IS UNKNOWN

GPCR, COMPLEX-LCP method, SBDD, drug design, XFEL, LCP-SFX, Ligand Exchange, Alprenolol, b2AR, beta2AR, MEMBRANE PROTEIN

MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADL
VMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIV
SGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQL

NIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNCNGVITKDEAEKLFNQDVDAAVRGILRN
AKLKPVYDSLDAVRRCALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLAKSRWYNQTPNRAKRVITTFRTGTWDAY

KFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCL
RRSSLK